Fig. 3.

Tu-2449 in B6C3F1 glioma model survival analysis. Groups of 10 female B6C3F1 mice (8 weeks of age) were implanted IC with 1E4 Tu-2449 tumor cells then dosed IC with vehicle (Control) or IC with Toca 511. Two separate experiments were performed with doses ranging from E3 to a dose level of E6 TU/g (A and B). Following 7 days, to allow spread of Toca 511, mice were treated IP BID for 4 consecutive days with either PBS or 5-FC 500 mg/kg or 50 mg/kg (low) as indicated. This cycle of 4 days on drug followed by 10 days off drug was repeated until the conclusion of the study. Survival analysis up to day 180 (A) or day 100 (B) was performed on each group.